Exelixis

Exelixis, Inc., founded in November 1994 and headquartered in Alameda, California, is a biotechnology company focused on genomics-based drug discovery and cancer treatments. The company's core mission is to maximize impact for patients by driving medical progress through integrated research, development, and commercial models. Exelixis is known for producing Cometriq, an FDA-approved treatment for medullary thyroid cancer that also shows clinical activity in various other metastatic cancers. Their market focus encompasses oncology, with a commitment to advancing their pipeline and fostering strategic partnerships.

Notable figures associated with Exelixis include Stelios Papadopoulos, Ph.D., serving as chairman, and Michael M. Morrissey, Ph.D., as president and CEO. The company is publicly traded on Nasdaq under the ticker EXEL and is a component of the S&P 400. Key achievements include a revenue of $1.435 billion and a net income of $0.231 billion in 2021. Exelixis has made significant strides in cancer treatment, notably through collaborations like the clinical trial with Arcus Biosciences, and continues to impact the biotechnology industry with its innovative approaches and strategic initiatives.